Cost-effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis

James D. Mancuso, D. W. Niebuhr, Kevin Frick, L. W. Keep, K. M. Anderson

Research output: Contribution to journalArticle

Abstract

SETTING: No cost-effectiveness studies of testing for latent tuberculosis infection have incorporated both targeted testing and the use of interferon-gamma release assays (IGRAs) in heterogeneous populations. OBJECTIVE: To examine the cost-effectiveness of universal vs. targeted and sequential testing strategies and the use of tuberculin skin testing (TST) vs. IGRAs. DESIGN: Using a decision-analytic model, incremental cost-effectiveness ratios were calculated in 2009 among nine potential strategies for screening recruits. A societal perspective was taken over a 20-year analytic horizon, discounting future costs at 3% annually. Sensitivity analyses were conducted to determine how changes in assumptions affected the estimates. RESULTS: Targeted strategies cost over US$250 000 per case prevented, whereas universal testing strategies cost over US$700 000 per incremental case prevented in base case and most sensitivity analyses. CONCLUSION: Targeted testing offered the best value in this population, although it was still relatively expensive compared to no testing. Sequential testing with both TST and IGRAs provided a poor incremental value compared to targeted and universal testing strategies. Targeted testing using TST was slightly more cost-effective than targeted testing using either QuantiFERON® -TB Gold In-Tube or T-SPOT® .TB, but these estimates were very sensitive to changes in model assumptions.

Original languageEnglish (US)
Pages (from-to)1223-1230
Number of pages8
JournalInternational Journal of Tuberculosis and Lung Disease
Volume15
Issue number9
DOIs
StatePublished - Sep 2011

Fingerprint

Latent Tuberculosis
Interferon-gamma Release Tests
Cost-Benefit Analysis
Tuberculin
Costs and Cost Analysis
Skin
Gold
Population

Keywords

  • Cost-effectiveness analysis
  • Recruit medicine
  • Tuberculosis screening

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Cost-effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis. / Mancuso, James D.; Niebuhr, D. W.; Frick, Kevin; Keep, L. W.; Anderson, K. M.

In: International Journal of Tuberculosis and Lung Disease, Vol. 15, No. 9, 09.2011, p. 1223-1230.

Research output: Contribution to journalArticle

Mancuso, James D. ; Niebuhr, D. W. ; Frick, Kevin ; Keep, L. W. ; Anderson, K. M. / Cost-effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis. In: International Journal of Tuberculosis and Lung Disease. 2011 ; Vol. 15, No. 9. pp. 1223-1230.
@article{199173723a234dc39affa5ea795ffd4e,
title = "Cost-effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis",
abstract = "SETTING: No cost-effectiveness studies of testing for latent tuberculosis infection have incorporated both targeted testing and the use of interferon-gamma release assays (IGRAs) in heterogeneous populations. OBJECTIVE: To examine the cost-effectiveness of universal vs. targeted and sequential testing strategies and the use of tuberculin skin testing (TST) vs. IGRAs. DESIGN: Using a decision-analytic model, incremental cost-effectiveness ratios were calculated in 2009 among nine potential strategies for screening recruits. A societal perspective was taken over a 20-year analytic horizon, discounting future costs at 3{\%} annually. Sensitivity analyses were conducted to determine how changes in assumptions affected the estimates. RESULTS: Targeted strategies cost over US$250 000 per case prevented, whereas universal testing strategies cost over US$700 000 per incremental case prevented in base case and most sensitivity analyses. CONCLUSION: Targeted testing offered the best value in this population, although it was still relatively expensive compared to no testing. Sequential testing with both TST and IGRAs provided a poor incremental value compared to targeted and universal testing strategies. Targeted testing using TST was slightly more cost-effective than targeted testing using either QuantiFERON{\circledR} -TB Gold In-Tube or T-SPOT{\circledR} .TB, but these estimates were very sensitive to changes in model assumptions.",
keywords = "Cost-effectiveness analysis, Recruit medicine, Tuberculosis screening",
author = "Mancuso, {James D.} and Niebuhr, {D. W.} and Kevin Frick and Keep, {L. W.} and Anderson, {K. M.}",
year = "2011",
month = "9",
doi = "10.5588/ijtld.10.0542",
language = "English (US)",
volume = "15",
pages = "1223--1230",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "9",

}

TY - JOUR

T1 - Cost-effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis

AU - Mancuso, James D.

AU - Niebuhr, D. W.

AU - Frick, Kevin

AU - Keep, L. W.

AU - Anderson, K. M.

PY - 2011/9

Y1 - 2011/9

N2 - SETTING: No cost-effectiveness studies of testing for latent tuberculosis infection have incorporated both targeted testing and the use of interferon-gamma release assays (IGRAs) in heterogeneous populations. OBJECTIVE: To examine the cost-effectiveness of universal vs. targeted and sequential testing strategies and the use of tuberculin skin testing (TST) vs. IGRAs. DESIGN: Using a decision-analytic model, incremental cost-effectiveness ratios were calculated in 2009 among nine potential strategies for screening recruits. A societal perspective was taken over a 20-year analytic horizon, discounting future costs at 3% annually. Sensitivity analyses were conducted to determine how changes in assumptions affected the estimates. RESULTS: Targeted strategies cost over US$250 000 per case prevented, whereas universal testing strategies cost over US$700 000 per incremental case prevented in base case and most sensitivity analyses. CONCLUSION: Targeted testing offered the best value in this population, although it was still relatively expensive compared to no testing. Sequential testing with both TST and IGRAs provided a poor incremental value compared to targeted and universal testing strategies. Targeted testing using TST was slightly more cost-effective than targeted testing using either QuantiFERON® -TB Gold In-Tube or T-SPOT® .TB, but these estimates were very sensitive to changes in model assumptions.

AB - SETTING: No cost-effectiveness studies of testing for latent tuberculosis infection have incorporated both targeted testing and the use of interferon-gamma release assays (IGRAs) in heterogeneous populations. OBJECTIVE: To examine the cost-effectiveness of universal vs. targeted and sequential testing strategies and the use of tuberculin skin testing (TST) vs. IGRAs. DESIGN: Using a decision-analytic model, incremental cost-effectiveness ratios were calculated in 2009 among nine potential strategies for screening recruits. A societal perspective was taken over a 20-year analytic horizon, discounting future costs at 3% annually. Sensitivity analyses were conducted to determine how changes in assumptions affected the estimates. RESULTS: Targeted strategies cost over US$250 000 per case prevented, whereas universal testing strategies cost over US$700 000 per incremental case prevented in base case and most sensitivity analyses. CONCLUSION: Targeted testing offered the best value in this population, although it was still relatively expensive compared to no testing. Sequential testing with both TST and IGRAs provided a poor incremental value compared to targeted and universal testing strategies. Targeted testing using TST was slightly more cost-effective than targeted testing using either QuantiFERON® -TB Gold In-Tube or T-SPOT® .TB, but these estimates were very sensitive to changes in model assumptions.

KW - Cost-effectiveness analysis

KW - Recruit medicine

KW - Tuberculosis screening

UR - http://www.scopus.com/inward/record.url?scp=80051683595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051683595&partnerID=8YFLogxK

U2 - 10.5588/ijtld.10.0542

DO - 10.5588/ijtld.10.0542

M3 - Article

C2 - 21943850

AN - SCOPUS:80051683595

VL - 15

SP - 1223

EP - 1230

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 9

ER -